&w=3840&q=100)
Over 40 mn women get maternity aid under PMMVY; drive till Aug 15: WCD
The ministry, in a statement , called it a reflection of the government's "sustained commitment to maternal and child health" as it announced the extension of a special registration drive under the scheme till August 15.
The ongoing door-to-door campaign, led by Anganwadi and ASHA workers, aims to ensure that all eligible pregnant and lactating women are enrolled on time. "The campaign is not only about ensuring access to financial benefits but also about encouraging positive attitudes towards the girl child," the ministry said in its statement.
PMMVY, a centrally sponsored scheme under Mission Shakti's 'Samarthya' sub-scheme, provides partial wage compensation to mothers through direct benefit transfer (DBT).
For the first child, a cash incentive of ₹5,000 is given in two installments, while for the second girl child, ₹6,000 is paid in a single installment after birth.
To enhance efficiency and transparency, the scheme has been integrated with PMMVYSoft which is a digital platform launched in March 2023.
This software uses Aadhaar-based authentication and NPCI verification to ensure that funds are directly transferred to the beneficiaries' Aadhaar-linked bank or post office accounts.
The revamped portal also features an Integrated Grievance Module, a multilingual toll-free helpline (14408), Aadhaar-based biometric authentication using Facial Recognition System (FRS), and an automated due-list to identify and reach out to potential beneficiaries, the statement said.
The ministry said the scheme's success lies in the coordinated efforts of field-level workers and state officials, adding that it remains committed to improving maternal nutrition, health-seeking behaviour, and gender equity through PMMVY.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.
Hans India
2 hours ago
- Hans India
District Administration Implements UNICEF Recommendations to Strengthen Child Welfare Services in Gadwal
Gadwal: District Collector B.M. Santhosh announced that the district administration is taking comprehensive measures to improve child welfare services in line with the recommendations made by the UNICEF team. On Tuesday, a review meeting on the implementation of the Supervised Supplementary Feeding Program was held at the IDOC Video Conference Hall. Officials from various departments, along with the UNICEF team, participated in the meeting. As part of their visit, the UNICEF team inspected the medicine store near the Gadwal Medical College, an Anganwadi center, and a Primary Sub-Center in Gattu Mandal. They evaluated the supply of medicines, the distribution of nutritional supplements, and the implementation of medical services. The UNICEF team briefed the Collector on their observations and appreciated the district's progress, particularly in identifying and addressing nutritional deficiencies among children. They lauded the district's effective mechanisms for detecting malnutrition in early stages. In response, the District Collector assured that all suggestions made by the UNICEF team would be carefully followed and used as a foundation to enhance the quality of services delivered at the district level. He emphasized that special attention would be given to children who are not responding to nutritional services or show signs of growth retardation, and appropriate corrective actions would be taken to restore their health. He further stated that awareness meetings would be conducted with self-help groups, Anganwadi workers, and ASHA workers to ensure a unified and coordinated approach. A clear and common message will be disseminated among all stakeholders to strengthen inter-departmental coordination. The Collector noted that, following UNICEF's guidance, the Supervised Supplementary Feeding Program will be implemented more effectively. Services such as distribution of Balamrutham Plus, medical support, nutrition, and health education will be delivered in a more integrated and efficient manner. The meeting was attended by Additional Collector Narsinga Rao, District Welfare Officer Sunanda, DPO Nagendram, District Medical Officer Siddappa, UNICEF team members, and other officials.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
